Sanj K. Patel, President & CEO at SYNAGEVA BIOPHARMA CORP (GEVA), sold 50,000 shares at $90.06 ($4.4M) on 2014-12-17, disclosed to the SEC on 2014-12-19.
Scheduled sale ($4.4M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $87.25 | 5,016 | $438K | 9.9% |
| 2 | $87.26 | 4,488 | $392K | 8.8% |
| 3 | $87.55 | 13,536 | $1.2M | 26.7% |
| 4 | $90.06 | 26,960 | $2.4M | 54.7% |
| Total | $88.85 avg | 50,000 | $4.4M | 100% |
| Filing → |
| KNSA | SELL | 2026-04-08 | $364K | — | Filing → |
| KNSA | SELL | 2025-10-22 | $20.0M | — | Filing → |
| KNSA | SELL | 2025-05-28 | $4.6M | — | Filing → |